(Q36185624)

12 August 2017

1 reference

title

Treatment of mantle cell lymphoma: targeting the microenvironment (English)

1 reference

12 August 2017

1 reference

Johannes Drach

1

1 reference

PubMed ID

16001955

12 August 2017

Sonja Seidl

series ordinal

2

1 reference

PubMed ID

16001955

12 August 2017

Hannes Kaufmann

series ordinal

3

1 reference

12 August 2017

1 June 2005

1 reference

Expert Review of Anticancer Therapy

12 August 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

12 August 2017

5

1 reference

12 August 2017

477-485

1 reference

12 August 2017

3

1 reference

Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis

12 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

The role of fludarabine in the treatment of follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Mechanisms of B-cell lymphoma pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

The role of the tumor microenvironment in hematological malignancies and implication for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Helicobacter pylori, T cells and cytokines: the "dangerous liaisons".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Thalidomide treatment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Thalidomide therapy induces response in relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.5.3.477

21 January 2018

Identifiers

DOI

10.1586/14737140.5.3.477

1 reference

12 August 2017

1 reference

PubMed ID

16001955